Dyadic International Expands Bio-Industrial Pipeline with New Enzyme Program
Dyadic International, Inc. has launched a proprietary industrial enzyme program aimed at cellulose processing, expanding its bio-industrial pipeline. The company plans to optimize this program through pilot-scale production and customer evaluation while pursuing commercialization via direct sales, collaborations, and licensing.
Theia Market Signal Identification - AI Assisted
Dyadic International, Inc. (NASDAQ: DYAI) announced the launch of a proprietary industrial enzyme program focused on cellulose processing, building on the success of its EN3ZYME™ product. The initiative utilizes the Dapibus™ platform, which employs a single microbial production strain, streamlining development and manufacturing processes.
Dyadic aims to commercialize the enzyme through various channels, including direct sales and partnerships. The program is intended for applications in pulp biorefining and nanocellulose production. Dyadic reported a 182% revenue increase for Q1 2026, amounting to $1.1 million.
Recent developments include the approval of a patent for its recombinant protein technology in Japan and the election of a new director. These factors may enhance investor interest and support the company’s long-term growth strategy.
Comments